E
Emily Castellanos
Researcher at Vanderbilt University Medical Center
Publications - 39
Citations - 1223
Emily Castellanos is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 11, co-authored 31 publications receiving 873 citations. Previous affiliations of Emily Castellanos include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Obese adults have visual attention bias for food cue images: evidence for altered reward system function
Emily Castellanos,Evonne J. Charboneau,Mary S. Dietrich,Sohee Park,Brendan P. Bradley,Karin Mogg,Ronald L. Cowan +6 more
TL;DR: Investigating whether the motivational salience of food cues differs between obese and normal-weight subjects in a manner consistent with altered reward system function in obesity found food cue incentive salience is elevated equally in normal- Weight and obese individuals during fasting.
Journal ArticleDOI
Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non–Small Cell Lung Cancer
TL;DR: Clinical trials of novel EGFR TKIs should prospectively account for the presence of uncommon mutation subtypes in study design, and the development of comprehensive bioinformatics‐driven tools to both analyze response in uncommon mutations subtypes and inform clinical decision making will be increasingly important.
Journal ArticleDOI
Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
Douglas B. Johnson,Mellissa J. Nixon,Yu Wang,Daniel Y. Wang,Emily Castellanos,Monica V. Estrada,Paula I. Ericsson-Gonzalez,Candace H Cote,Roberto Salgado,Violeta Sanchez,Phillip T. Dean,Susan R. Opalenik,Daniel M. Schreeder,David L. Rimm,Ju Young Kim,Jennifer Bordeaux,Sherene Loi,Leora Horn,Melinda E. Sanders,P. Brent Ferrell,Yaomin Xu,Jeffrey A. Sosman,Randall S. Davis,Justin M. Balko +23 more
TL;DR: Data suggest a MHC-II-mediated context-dependent mechanism of adaptive resistance to PD-1-targeting immunotherapy, which is likely to be a novel inhibitory function of FCRL6 engagement, identifying it as an immunotherapy target.
Journal ArticleDOI
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors.
Changxia Shao,Gerald Li,Lingkang Huang,Scott K. Pruitt,Emily Castellanos,Garrett M. Frampton,Kenneth R. Carson,Tamara Snow,Gaurav Singal,David Fabrizio,Brian M. Alexander,F. Jin,Wei Zhou +12 more
TL;DR: It is suggested that TMB-H was not associated with overall survival in patients with 10 rare solid tumor types in the absence of immunotherapy.
Journal ArticleDOI
Response to salvage chemotherapy following exposure to immune checkpoint inhibitors in patients with non-small cell lung cancer.
TL;DR: Evaluating responses to chemotherapy in patients who had progressed on a checkpoint inhibitor in patients with stage IV NSCLC who received salvage chemotherapy following PD-1/PD-L1 inhibitors found 82 patients met eligibility criteria.